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Ferroportin (FPN1) is the sole iron exporter in mammals, but its cell-specific function and regulation are still elusive. This
study examined FPN1 expression in human macrophages, the cells that are primarily responsible on a daily basis for plasma
iron turnover and are central in the pathogenesis of ferroportin disease (FD), the disease attributed to lack-of-function FPN1
mutations. We characterized FPN1 protein expression and traffic by confocal microscopy, western blotting, gel filtration, and
immunoprecipitation studies in macrophages from control blood donors (donor) and patients with either FPN1 p.A77D,
p.G80S, and p.Val162del lack-of-function or p.A69T gain-of-function mutations. We found that in normal macrophages,
FPN1 cycles in the early endocytic compartment does not multimerize and is promptly degraded by hepcidin (Hepc), its phys-
iological inhibitor, within 3-6 hours. In FD macrophages, endogenous FPN1 showed a similar localization, except for greater
accumulation in lysosomes. However, in contrast with previous studies using overexpressed mutant protein in cell lines, FPN1
could still reach the cell surface and be normally internalized and degraded upon exposure to Hepc. However, when FD mac-
rophages were exposed to large amounts of heme iron, in contrast to donor and p.A69T macrophages, FPN1 could no longer
reach the cell surface, leading to intracellular iron retention. Conclusion: FPN1 cycles as a monomer within the endocytic/plas-
ma membrane compartment and responds to its physiological inhibitor, Hepc, in both control and FD cells. However, in FD,
FPN1 fails to reach the cell surface when cells undergo high iron turnover. Our findings provide a basis for the FD character-
ized by a preserved iron transfer in the enterocytes (i.e., cells with low iron turnover) and iron retention in cells exposed to
high iron flux, such as liver and spleen macrophages. (HEPATOLOGY 2017;65:1512-1525)
Ferroportin (FPN1), the only iron exporteridentified in mammals, is involved in irontransfer from the external milieu and from
internal sites of iron storage and recycling into the
bloodstream.(1) At the systemic level, FPN1 is mainly
controlled posttranslationally by hepcidin (Hepc),
which binds to FPN1 at the cell surface and causes its
degradation.(2)
The predicted molecular mass of purified human
FPN1 is approximately 696 6.2 kDa.(3) Yet, in mouse
tissues, different FPN1 molecular weight (MW) forms
have been detected in liver, duodenum, and spleen.(4)
FPN1 topology and membrane organization has also
been addressed with controversial results concerning
localization of the N- and C-termini and number of
transmembrane segments.(3,5-13)
Abbreviations: aa, amino acid; BME, ß-mercaptoethanol; BPB, bromophenol blue; DAPI, 4’,6-diamidino-2-phenylindole; Dx, dexamethasone phos-
phate; EDTA, ethylenediaminetetraacetic acid; EEA-1, early endosome antigen 1; eEF1A, eukaryotic elongation factor 1A; eIF6, eukaryotic translation
initiation factor 6; Endo H, endoglycosidase H; FD, ferroportin disease; FPN1, ferroportin; Hb, hemoglobin; Hepc, hepcidin; IAA, iodoacetamide; IP,
Immunoprecipitation; LAMP-1, lysosomal-associated membrane protein 1; MDCK, Madin-Darby canine kidney cells; MW, molecular weight; Na,K-
ATPase, sodium-potassium pump; PBMCs, peripheral blood mononuclear cells; PBS, phosphate-buffered saline; PNGase F, peptide N-glycosidase F;
RT, room temperature; SDS, sodium dodecyl sulfate; SDS-PAGE, SDS/polyacrylamide gel electrophoresis; TE, total protein extract; TEP, trypsin-
EDTA-PBS; TfR1, transferrin receptor 1; WB, western blotting; WT, wild type.
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Dissecting the basis of the human disease attributed to
lack of FPN1, the so-called ferroportin disease (FD),(14)
would be informative also for understanding protein biol-
ogy and function. FD is an autosomal-dominant disorder
attributed to lack-of-function mutations of FPN1 and is
characterized bymarked iron accumulation in tissuemac-
rophages, preserved intestinal iron transfer, and subclini-
cal anemia.(15,16) Unusual gain-of-function mutations of
FPN1 (such as N144H, C326Y, and C326S)(17-19) pre-
vent Hepc binding and/or FPN1 internalization, so that,
although hepcidin is produced normally, FPN1 is resis-
tant to its inhibitory activity and persistently exports iron
toward the bloodstream, ultimately resulting in syndrome
identical to hemochromatosis but distinct from FD.
A number of in vitro studies, mostly using overex-
pressed exogenous wild-type (WT) and mutant FPN1
in a variety of cell lines, have investigated FPN1 biology
and function and have provided valuable information on
the effect of different FPN1 mutants on protein traffic
and iron transfer capability.(3,5-7,9,12,20-26)
In this context, it has been actively debated whether
FPN1 haploinsufficiency would explain FD or whether
the disease results from a dominant-negative effect. It has
been argued that if haploinsufficiency was the explanation
for FD, then nonsense mutations should also result in the
disorder; however, so far, the vast majority of reported
mutations in FD are missense mutations.(27) Additionally,
a targeted gene deletion in the murine Fpn1 gene has little
effect in heterozygous animals,(28) whereas the flatiron (ffe)
mouse, with a missense mutation in Fpn1 that affects its
localization and iron export activity when overexpressed in
vitro, presents a phenotype similar to human patients.(8)
Finally, exogenous tagged FPN1 in vitro forms multimers
and mutant Fpn1 prevents cell membrane localization of
WT Fpn1.(8,21,29) However, other studies from different
groups reached opposite conclusions, showing that Fpn1 is
a monomer in cultured cells(3,30,31) and in vivo inmice.(32)
Given that it is formally possible that FD in mice
cannot recapitulate the human disease and that
artificial overexpression of FPN1 in cultured cells may
not reproduce the physiological state, we directly inves-
tigated FPN1 expression in human macrophages from
control blood donors and from patients with FD.
Patients and Methods
PATIENTS
The study included members of four different pedi-
grees carrying the p.A77D, p.G80S, p.Val162del, and
p.A69T FPN1 mutations (Fig. 1). Blood was also col-
lected from age- and sex-matched blood donors with
normal iron status. The study was approved by the
ethics committee at the University of Modena (Mode-
na, Italy) and Reggio Emilia.
PROCESSING OF BIOPSY
SPECIMENS
Five-micrometer liver biopsy sections were
immersed in a 4% solution of paraformaldehyde in
buffer/L 0.1 mol of phosphate-buffered saline (PBS;
pH7.4), embedded in paraffin, and stained with Perls’
Prussian blue for the presence of iron.
CELL CULTURE
Peripheral Blood Mononuclear Cells
Isolation and Culture
Monocytes were obtained by gradient centrifugation
of peripheral blood mononuclear cells (PBMCs) and
cultured as described.(33) At day 3, 25 ng/mL of granu-
locyte colony-stimulating factor (Invitrogen Corpora-
tion, Carlsbad, CA, USA) were added, and
macrophages were selected by adhesion. Medium and
all reagents were endotoxin free.
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Macrophage lineage characterization was based on
morphological study and expression of the
monocytes-macrophages lineage marker, CD14 (see
below).
To block dynamin-dependent endocytosis,(34)in
vitro differentiated macrophages were treated with 40
and 400lM of dynasore (Enzo Life Sciences, Lausen,
Switzerland) for 30 minutes and processed for
immunoflurescence.
Cells were also treated for 1-24 hours with 700 nM
of Hepc (Peptide Institute, Minoh-shi Osaka, Japan)
and subjected to immunofluorescence.
In specific experiments, cells were preincubated for
18 hours with 0.25mM of dexamethasone phosphate
(Dx; Sigma-Aldrich, St. Louis, MO, USA), a known
stimulator of CD163 expression and hemoglobin (Hb)
uptake by macrophages,(35) and then incubated for 6
hours with 20lg/mL of bovine Hb (Sigma-Aldrich).
Donor macrophages were also treated with aged red
blood cells as reported.(36) Cells were harvested and
processed for immunofluorescence.
Cellular ferritin content and iron in the medium
were assayed after overnight incubation as specified
below.
FPN-1-Expressing Cell Lines
Full-length FPN1 complementary DNA was gener-
ated by RT-PCR amplification of human fibroblast
RNA. DNA gene sequencing by Sanger confirmed
that the donor human fibroblast SCL40A1 gene was
WT. The FPN1 coding region was sequenced and
subcloned into the pcDNA3.1/Hygro expression vec-
tor (Invitrogen, Groningen, The Netherlands), in
order to obtain FPN1 untagged or tagged at the C-
terminal with V5 epitope. The pA77D FPN1 was
obtained by mutagenesis using the QuickChange Site-
Directed Mutagenesis kit (Stratagene, Milan, Italy).
Madin-Darby canine kidney cells (MDCK) cells stably
expressing WT, pA77D FPN1, and FPN1-V5 were
obtained by transfecting MDCK cells with the Trans-
fection Reagent Selector Kit Effectane (Qiagen,
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FIG. 1. Liver and macrophage phenotype of FD patients. (A) Liver biopsy sections from patients with FD investigated in this study
stained with Perls’ Prussian blue for iron. Pictures show the classic iron-laden phenotype of Kupffer cells (arrows) in p.A77D,
p.G80S, and pVal162del FD patients. On the contrary, microphotograph from a patient carrying the p.A69T FPN1 mutation shows
iron accumulation in hepatocytes, but not in Kupffer cells. Donor and disease PBMC-derived macrophages (B) express after 7 days
the CD14 macrophage-specific marker and (C) retain normal phagocytic activity when incubated in the presence of autofluorescent
beads (see Patients and Methods). (D) Ferritin content of representative macrophage preparations. The amount of intracellular ferritin
is doubled in macrophages from lack-of-function FD patients and halved in macrophages from patients carrying the Hepc-resistant
p.A69T mutation. Ferritin values are mean6 SEM of three different cell preparations from a representative patient as compared to
cell preparations from a blood donor. *P< 0.05.
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Milan, Italy), according to the manufacturer’s
instructions.
Differentiation of THP-1 Cell Line
In order to differentiate the human leukemia cell
line, THP-1, to macrophages, cells were incubated in
RPMI 1640 medium containing phorbol 12-myristate
13-acetate at 5 ng/mL for 48 hours, as reported by
Park et al.(37)
IMMUNOPRECIPITATION AND
WESTERN BLOTTING ANALYSIS
Whole-cell lysates from PMBC-derived macro-
phages, THP1 (human leukemia cell line), MDCK
cells, and MDCK stably transfected with WT, pA77D
human FPN1, and human FPN1-V5 were subjected
to western blotting (WB) analysis using the ECL
Advance WB Detection Kit (GE Healthcare Life Sci-
ences, Milan, Italy) according to the manufacturer’s
instructions. Total proteins were extracted with
trypsin-EDTA-PBS (TEP) lysis buffer (150mm of
NaCl, 10mM of Tris [pH5 8], 10mM of ethylene-
diaminetetraacetic acid [EDTA], and 1% Triton X-
100) supplemented with 1:100 protease inhibitor cock-
tail (Sigma-Aldrich) for standard WB, or, in specific
experiments, supplemented with 50mM of iodoaceta-
mide (IAA; Sigma-Aldrich). After centrifugation at
13,000g at 4 8C for 15 minutes, the supernatant was
collected and protein concentration assayed by the
Bradford method. In specific experiments, samples
were heated 10 minutes at 100 8C, in loading buffer
with 100mM of 1,4-dithiotheitol or 2.5% b-
mercaptoethanol (BME). The antibodies used in WB
analysis were as follows: rabbit anti-FPN1 that recog-
nizes a 19-amino-acid (aa) epitope on FPN1 C-
terminal (1:10,000; Alpha Diagnostic International,
San Antonio, TX), or rabbit anti-FPN1 antibody
(1:2,000) that recognizes an epitope 223-303 aa local-
ized on an intracellular loop beetwen VI and VII trans-
membrane domain, kindly provided by D.J. Haile,(38)
followed by horseradish peroxidase–conjugated swine
anti-rabbit antibody (1:10,000; Dako Cytomation,
Glostrup, Denmark), as secondary antibody.
Immunoprecipitation (IP) studies were performed
as described.(32) In brief, FPN1 in cleared lysates was
immunoprecipitated by adding 5mg/mg of rabbit
anti-FPN1 antibody for 2 hours at 4 8C, followed by
overnight incubation with 50mL/mg of equilibrated
protein A-Sepharose 4B/protein G-Sepharose resin
(Sigma-Aldrich). The beads were extensively washed
with TEP buffer and protein solubilized in protein
loading buffer (sodium dodecyl sulfate [SDS] 2%,
glycerol 10%, BME 2.5%, 62.5mM of Tris-HCl
[pH5 6.8], and bromophenol blue [BPB] 0.01%) for
30 minutes, at room temperature (RT). Total protein
extracts (25 mg) and immunoprecipitates were run on
10% SDS-PAGE (polyacrylamide gel electrophoresis)
and blotted onto nitrocellulose membrane at 150
mAmp overnight, at RT.
GEL FILTRATION
Macrophage extracts in TEP lysis buffer were load-
ed on a Superose 12 10/300 GL column (GE Health-
care Life Sciences). Chromatography was run at a flow
rate of 1mL/min, and fractions of 1.5mL were eluted.
After trichloroacetic acid precipitation, each fraction
was directly loaded on SDS-PAGE and probed with
rabbit anti-Fpn1 or rabbit anti-eEF1A (eukaryotic
elongation factor 1A; Cell Signaling Technology) or
mouse anti-eIF6 (eukaryotic translation initiation fac-
tor 6)(39) antibodies.
MEMBRANE PROTEIN
BIOTINYLATION
Macrophages and human liver hepatocellular carci-
noma cell line (HepG2) were incubated in ice with
sulfo-NHS-Biotin (Pierce Protein Biology–Thermo
Fisher Scientific Inc, Rockford, IL) at a concentration
of 2mM diluted in PBS for 30 minutes; afterward, the
labeling reaction was blocked with cell-culture medium
and cells washed with PBS. Total proteins were
extracted with TEP buffer or buffer 2 (150mm of
NaCl, 100mM of phosphate, 1% Triton-X, and
10mM of EDTA) supplemented with a protease
inhibitor cocktail (1:100; Sigma-Aldrich). Total pro-
tein extracts were then incubated for 18 hours at 4 8C
with agarose beads conjugated to streptavidin (Pierce
Protein Biology–Thermo Fisher Scientific), and, after
repeated washing with lysis buffer, samples were eluted
in protein loading buffer (2% SDS, 62.5mM of
Tris base [pH5 6.8], 10% glycerol, 2.5% 2-
mercaptoethanol, and BPB 0.01%), under went shak-
ing for 30 minutes at RT and for an additional 30
minutes at 37 8C. Total protein extracts (25 lg) and
eluted samples were subjected to SDS-PAGE followed
by WB analysis, as described.
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IMMUNOFLUORESCENCE
Cells were washed with PBS and fixed in cold (t5 –
20 8C) 100% methanol for 10 minutes at RT and first
incubated in blocking solution (4% goat serum in PBS)
for 1 hour at RT and then with the primary and second-
ary antibody diluted in blocking solution or PBS for one
additional hour. To detect Hepc expression, incubation
with the primary antibody was performed for 18 hours at
4 8C. The primary antibodies used were: mouse antihu-
man CD14 (1:20; Chemicon International, Temecula,
CA); mouse anti–sodium-potassium pump (Na,K-
ATPase [plasma membrane marker]; 1:500, Abcam,
Cambridge, UK); rabbit anticalnexin (1:200 [endoplas-
mic reticulum marker]; Sigma-Aldrich); rabbit anti-
golgin-97 (1:100 [Golgi marker]; Molecular Probes,
Leiden, The Netherlands )(Golgi marker); rabbit anti–
early endosome antigen 1 (EEA-1; 1:200; Abcam,
Cambridge, UK), as an early endosomes marker; rat
anti–lysosomal-associated membrane protein 1 (LAMP-
1 [lysosome marker]; 1:50; Fitzgerald Industries Interna-
tional, Concord, MA); rabbit anti-FPN1 (1:50 PBS;
Alpha Diagnostic International, San Antonio, TX,
USA); rabbit anti–human transferrin receptor 1 (TfR1;
1:50; Santa Cruz Biotechnology, Santa Cruz, CA); and
rabbit anti-Hepc (1:50 PBS; Alpha Diagnostic Interna-
tional). Secondary antibodies were: goat antimouse
Alexa 594 coniugated (1:400; Sigma-Aldrich); goat anti-
rabbit Alexa 594 coniugated (1:300; Sigma-Aldrich);
rabbit antirat (1:50; Dako Cytomation, Glostrup, Den-
mark); and goat antirabbit Alexa 488 coniugated (1:200;
Sigma-Aldrich). Afterward, cells were incubated in 4’,6-
diamidino-2-phenylindole (DAPI) 2 ng/lL of PBS for
5 minutes at RT to highlight nuclei and analyzed by a
Leica confocal microscopy.
FERRITIN AND IRON
MEASUREMENTS
Total proteins were extracted from macrophages
with lysis buffer TEP (150mm of NaCl, 10mM of Tris
[pH5 8], 0.5% Triton-X, and 1mM of EDTA) sup-
plemented with protease inhibitor cocktail (1:100; Sig-
ma-Aldrich). After centrifugation at 13,000g at 4 8C for
15 minutes, the supernatant was collected and protein
assayed by the Bradford method. Ferritin was measured
by enhanced particle immunoturbidimetric assay
(Roche Diagnostics, Indianapolis, IN, USA), and the
values obtained were normalized to the protein content.
For iron assay, cell media were collected and cell
debris were removed by centrifugation. After
lyophilization, samples were digested in ultrapure 65%
nitric acid for 18 hours at RT and for an additional 2
hours at 120 8C in the presence of hydrogen peroxide
(Sigma-Aldrich) to improve mineralization. Finally,
samples were diluted with ultrapure water and read in
triplicate using quadrupole inductively coupled plasma
mass spectrometry (Thermo Scientific, Waltham, MA,
USA).
STATISTICAL ANALYSIS
All analyses were conducted using Prism 5 for mac
OS X (version 5.0a) software. All comparisons were
made by using nonparametric statistical tests (Graph-
Pad Software Inc., La Jolla, CA, USA).
Results
PBMCs were obtained from blood donors and
patients diagnosed with an FD based on clinical,
genetic, and histopathological evaluation. As expected,
liver histology showed a predominant iron-laden
Kupffer cell pattern typical of the FD, in patients car-
rying the p.A77D, p.G80S, and p.Val162del FPN1
mutations, whereas patients carrying the Hepc-
resistant p.A69T FPN1 mutation showed iron-spared
Kupffer cells and selective iron accumulation in hepa-
tocytes (Fig. 1A). As to the PBMC studies, we con-
firmed that after 7 days of culture, adherent cells
expressed the macrophage lineage CD14 marker (Fig.
1B), preserved a phagocytic activity (Fig. 1C), and
retained in culture the iron phenotype of the original
patient, showing increased ferritin iron content in FD
macrophages and lower in p.A69T macrophages (Fig.
1D). Individual patients’ macrophages were studied in
different occasions, and each time we also ran the
experiment in a matched donor.
CHARACTERIZATION OF FPN1
EXPRESSION IN HUMAN
MACROPHAGES AND CELL LINES
In preliminary experiments, we verified whether the
anti-FPN1 antibody could detect both human WT
and mutant FPN1. To this purpose, MCDK cells, in
which FPN1 protein is normally undetectable and
have been previously used to validate anti-FPN1 anti-
bodies,(28) were stably transfected with WT or A77D
mutant human FPN1. In both cases, a predominant
FPN1 100-kDa MW form was identified by WB
(Fig. 2A, lanes 2 and 3), as well as a 65-kDa band
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comigrating with mouse spleen FPN1 (Fig. 2A, lanes
2, 3, and 5). A similar 100-kDa MW form was also
found in a human monocytic cell line (THP-1; Fig.
2A, lane 4, arrow), whereas in mouse spleen, a 65-
kDa MW band was identified by the same antibody
(Fig. 2A, lane 5, arrow). In total protein extracts (TE)
of donor macrophages, in addition to the 100-kDa
form (Fig. 2B, lane 3a), 55-kDa MW and 210-kDa
MW bands were detected (Fig. 2B). All these forms,
that is, the 55-kDa MW, 100-kDa MW, and 210-
kDa MW, may represent aggregates of unfolded 55-
kDa monomers that multimerize through their multiple
transmembrane hydrophobic domains.(40,41) Important-
ly, heating in the presence of the reducing agent, IAA,
that reduces artifactual postlysis aggregation led to the
disappearance of the 210-kDa MW band, the reduction
of the 55-kDa and 100-kDa bands, and the enrich-
ment in the expected 65-kDa band (Fig. 2B, lane 2b).
Next, we performed gel filtration assays on macrophage
extracts (Fig. 2C). The expected 65-kDa band (b) parti-
tioned in fraction 5, consistent with a monomeric form,
and in fraction 2, consistent with its presence in a larger
complex,250 kDa (e.g., solubilized microsomal mem-
branes). The 100-kDa form (a) enriched in fraction 3.
The 55-kDa band (c) partitioned throughout the gel
filtration (Fig. 2C), suggesting that it is unfolded or
prone to form artifactual intermediates. eEF1A, used as
a 50-kDa control, partitioned in fraction 2 containing
ribosomes, and in monomeric form in fraction 5 as
expected, with trailing attributed to solubilization con-
ditions. eIF6, a 27-kDa protein that may form dimers
and trimers in native filtration, here used as a 27- to 81-
kDa marker, partitioned in fractions 4 and 5. These
data, taken together, suggest that FPN1 is a multiple-
pass transmembrane protein that may aggregate ex vivo,
but it exists, in vivo, in two stable forms, a monomeric
one, and one associated with high-MW structures/
microsomal membranes.
Specificity of the anti-FPN1 antibody was proved
by the peptide competition experiments showing the
disappearance of the macrophage- and spleen-specific
bands following preabsorption of the anti-FPN1 anti-
body with a control peptide (Supporting Figs. S1A
and S2B) and by the identification of the same WB
pattern using two different anti-FPN1 antibodies
(Supporting Fig. S2A). In addition, experiments in
HepG2 cells transfected with FPN1-specific small
interfering RNA showed a decrease of the relevant
FPN1 bands as detected by WB (Supporting Fig.
S1C). When analyzing FPN1 expression in TE
extracts from diseased macrophages by WB, we found
the same FPN1 expression pattern as in donor macro-
phages (Fig. 2D). All FPN1 electrophoretic forms
were also detected in biotinylated human macrophage
membrane protein preparations (Fig. 2E).
To investigate whether FPN1 was glycosylated, we
subjectedmacrophage protein extracts to enzymatic diges-
tion with peptide N-glycosidase F (PGNaseF) and endo-
glycosidase H (EndoH). Supporting Fig. S3 shows that
whereas mouse spleen FPN1 was fully digested by
PNGase F (Supporting Fig. S3A, lane 1 and 2), as
reported,(4) HepG2-FPN1was only partly digested (Sup-
porting Fig. S3B, lane 3), whereas human donor and FD
macrophages as well as THP-1-FPN1 were resistant to
enzymatic digestion (Supporting Fig. S3C,D).
DISTINCT SUBCELLULAR
LOCALIZATION OF FPN1 IN
MACROPHAGES FROM BLOOD
DONORS AND FD PATIENTS
In donor macrophages, using an immunofluores-
cence colocalization approach, we found that FPN1 was
mostly localized in the early endosome compartment
and barely detectable at the plasma membrane (Fig. 3A,
Donor, merge panel). Interestingly, also in FD macro-
phages (from patients with p.A77D, p.G80S, and
p.Val162del), the immunofluorescence pattern showed
a similar distribution except for a higher amount of
FPN1 stain in the lysosomal compartment (Fig. 3A).
This was not the case for p.A69T macrophages, which
presented an FPN1 immunofluorescence pattern iden-
tical to that of donor macrophages.
Using TfR1, a marker for the early/recycling endosome
compartment, we found that FPN1 colocalizes with
TfR1, indicating that FPN1 traffics within the early/recy-
cling endosome compartment (Fig. 3B). In fact, treat-
ment of macrophages with dynasore, an inhibitor of
dynamin-dependent endocytosis, led to amarked increase
of plasma membrane localization of both TfR1 and
FPN1, with almost no residual signal in the cytoplasm, in
both normal and diseasedmacrophages (Fig. 3C).
RESPONSE TO Hepc-INDUCED
FPN1 DEGRADATION IN
NORMAL AND DISEASED
MACROPHAGES
Exposure of donor macrophages to Hepc, the physi-
ological inhibitor of FPN1, led to a progressive FPN1
degradation starting at 3 hours and peaking at 6
hours, with a full protein re-expression at 24 hours
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(Fig. 4A). As expected, in p.A69T mutant cells,
FPN1 signal was still present after 3-6 hours Hepc
exposure, suggesting that FPN1 was indeed resistant
to Hepc inhibition. Apparently, FPN1 stain persisted
after 3-6 hours of exposure to hepcidin in all FD mac-
rophages and showed some decrease only in G80S
macrophages at 6 hours of exposure (see Discussion).
Hepc/FPN1 colocalization studies indicated that
upon Hepc exposure in donor macrophages, FPN1 is
first recruited to the plasma membrane (Fig. 4B, 1
hour, donor panel), internalized with Hepc, and final-
ly degraded (Fig. 4B, 3 hours, donor panel). Interest-
ingly, also in lack-of-function mutant macrophages,
FPN1 was recruited to the plasma membrane (Fig.
4B, p.G80S panel), although to a lesser extent than in
donors, and normally internalized with Hepc
(although in somewhat larger cytoplasmic vesicles
than in donor macrophages).
We then explored the early steps of Hepc/FPN1 biolo-
gy and FPN1 degradation. After exposure of macrophages
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FIG. 2. Characterization of human FPN1. (A) WB analysis for FPN1 in whole-cell lysates from MDCK cells, MDCK stably trans-
fected with WT (MDCK-FPN1) or pA77D (MDCK-FPN1 pA77D) human FPN1 and THP1 cells (THP1) showing different
MW forms of FPN1 (arrows; see text for details). (B) WB analysis of whole-cell lysates of healthy donor macrophages extracted with
or without IAA, a compound that avoids oxidation of reduced disulfide bonds, and subjected or not to heating (see Patients and
Methods for details). The 100- and 55-kDa MW forms of FPN1 were unaffected by IAA and/or heating (lanes 1 and 4), whereas
a 210-kDa MW form originated a 65-kDa MW form after IAA/heating (lane 2; see text for details). a, b, and c on the right indicate
the different electrophoretic forms of FPN1 (see panel C and text for discussion). (C) Gel filtration chromatography fractions from
macrophage extracts loaded on SDS-PAGE and probed with rabbit anti-FPN1 or rabbit anti-eEF1A or mouse anti-eIF6 antibodies
(see Materials and Methods for details). FPN1 protein migration is consistent with a monomeric form and with association with
high-MW structures (see text for details). eEF1A and eIF6 were used as control marker (M1 and M2). eEF1A is 50 kDa; trailing to
lower fractions is attributed to detergents. eIF6 is 27 kDa MW that, in these conditions, behaves as monomer-dimer-trimer (27-81
kDa). a, b, and c on the left indicate the different electrophoretic forms of FPN1 (see panel B and text for discussion). (D) WB anal-
ysis of FPN1 in whole-cell lysates from donor and patient (p.A77D, p.Val162del, p.G80S, and p.A69T) macrophages showing consis-
tent identification of the two main 100- and 55-KDa MW FPN1 forms (lanes 1 through 5). (E) WB analysis identifies the same two
main 100-kDa and 50-kDa MW forms of FPN1 in plasma membrane proteins from both donor and patients’ macrophages after
biotinylation and purification with streptavidin agarose beads. Abbreviation: BP, biotinylated proteins.
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to Hepc for 6 hours (Fig. 4C, Hepc panel), the 100- and
55-kDa MW FPN1 form was no longer detectable,
whereas a 60-kDa MW FPN1 form (Fig. 4C, asterisk)
appeared, both in normal and diseased macrophages (Fig.
4C, lanes 8 and 10 vs. lanes 2 and 4, respectively), but this
was not the case with p.A69T “Hepc-resistant” macro-
phages (Fig. 4C, lanes 11 and 12).
DISTINCT PLASMA MEMBRANE
EXPRESSION OF FPN1 IN
PATIENT MACROPHAGES IN
RESPONSE TO Hb-IRON
Hb-iron is a known stimulus for FPN1 expression
and traffic to the plasma membrane.(41) We preliminary
tested the response of human macrophages to different
heme sources, namely, Hb and aged red blood cells. In
both settings, we found a similar shift of FPN1 toward
the plasma membrane (Fig. 5A). However, attributed
to better control and reproducibility of the experimental
procedures, we opted for the use of Hb in the following
experiments in which macrophages were also incubated
in the presence Dx, a known inducer of CD163 expres-
sion and Hb uptake.(35) In donor macrophages, Hb-Dx
treatment led to a marked expression of FPN1 at the
plasma membrane, as assessed by coimmunostaining
with an antibody against Na,K-ATPase, a plasma
membrane marker (Fig. 5B). However, in both p.G80S
and p.A77D macrophages, Hb-Dx exposure was unable
to recruit FPN1 to the plasma membrane, whereas it
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FIG. 3. WT and mutant FPN1 cycles in the early endosome/plasma membrane compartment in human macrophages. (A) Coimmu-
nofluorescence staining of FPN1 (green) with markers (red) for early endosomes, EE (EEA-1), lysosomes (LAMP-1), plasma mem-
brane, PM (Na,K-ATPase), Golgi (golgin-97), and endoplasmatic reticulum, ER (calnexin), shows that FPN1 colocalizes with early
endosomes and lysosomes (merge panels, yellow) in p.A77D, p.G80S, and pVal162del macrophages, whereas it is almost exclusively
localized in the EE compartment, in p.A69T and donor macrophages. (B) Coimmunostaining of FPN1 (green) with TfR1 (red; a
marker for the early endocytic recycling compartment) shows that FPN1 colocalizes with TfR1 in donor as well as in p.G80S and
p.A77D macrophages. (C) Treatment of macrophages from donors and p.A77D patients with dynasore to block dynamin-dependent
endocytosis leads to accumulation of both FPN1 and TFR1 in the PM compartment.
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dramatically increased cell membrane expression of
FPN1 in p.A69T macrophages (Fig. 5B, merge panel).
In agreement with previous experiments, when donor
and p.A69T macrophages were exposed to Hb-Dx,
both early endosomes and FPN1 readily shifted to the
plasma membrane (Fig. 5C, merge panel), whereas, in
p.G80S macrophages, whereas early endosome rapidly
moved to the cell membrane, FPN1 largely remained in
the cytoplasm (Fig. 5C, merge panel). Under these cir-
cumstances, intracellular ferritin content appreciably
decreased in Hb-Dx-treated donor cells whereas it did
not change in G80S macrophages and slightly increased
in A77D macrophages (Fig. 5D), indicating intracellu-
lar iron retention in FD macrophages. Accordingly,
iron efflux in the medium significantly increased in
donor macrophages, but did not change in G80S and
visibly decreased in A77D macrophages (Fig. 5E).
Importantly, upon heme exposure, we did not detected
higher MW forms of FPN (Fig. 5F), indicating that,
even during strong induction of protein traffic to the
cell surface, FPN1 does not multimerize and remains in
the expected MW forms.
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FIG. 4. Effect of Hepc on FPN1 expression and localization. (A) Immunofluorescence time-course analysis of FPN1 (green) in mac-
rophages from healthy donors and p.A77D, p.Val162del, p.G80S, and p.A69T patients after incubation with Hepc. In donor macro-
phages, Hepc-induced FPN1 degradation starts at 3 hours and peaks at 6 hours, with full protein re-expression at 24 hours. As
expected, in Hepc-resistant p.A69T mutant cells, FPN1 is not degraded after 3-6 hours of Hepc exposure. Yet, FD macrophages
showed a persistent FPN1 staining at the same time points (see text for comments). (B) FPN1-Hepc colocalization studies by immu-
nofluorescence show that both in donor and p.G80S macrophages, after 1 hour of hepcidin exposure, FPN1 (green) is recruited to the
plasma membrane and colocalizes with Hepc (red), whereas after 3 hours both Hepc and FPN1 are internalized in cytoplasmic
vesicles. (C) WB analysis of total protein extracts (INPUT) immunoprecipitated with an anti-FPN1 antibody from donor or diseased
macrophages incubated for 6 hours in the absence (control panel) or presence of Hepc (Hepc panel). After exposure of macrophages
to Hepc, an FPN1 form of around 62 kDa appears (stars in lanes 8 and 10). Arrows indicate specific signal for FPN1 and IgG.
Abbreviations: Ig, immunoglobulin; IgG, immunoglobulin G.
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Discussion
We found that in normal human macrophages,
FPN1 is largely localized in the early endosomal
cycling compartment within classic endocytic vesicle
containing TfR1, whereas a marginal fraction is
diverted to late endosomes and lysosomes for degrada-
tion. In human macrophages and HepG2 cells, we
consistently detected two major bands at 100-kDa
MW and 55-kDa MW band by SDS-PAGE. These
bands, however, most likely form during lysis, given
that they are reduced by heating in the presence of
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FIG. 5. Hb treatment leads to FPN1 membrane targeting in donor and Hepc-resistant FPN1—but not in lack-of-function FD mac-
rophages, which fail to export iron. (A) Macrophages from healthy donors were incubated in the absence (Control) or presence of
aged erythrocytes (Aged Red Cells), or of Dx1Hb. Coimmunofluorescence staining of FPN1 (green) and nucleus (blue) shows that
both treatments mobilize the FPN1 to the periphery of the cell. (B) Macrophages from healthy donors and patients carrying mutant
FPN1 (p.G80S, p.A77D, and p.A69T) were incubated in the absence (Control) or presence of Dx, Hb, or Dx1Hb (see Patients and
Methods for details). Coimmunofluorescence staining of FPN1 (green) and Na,K-ATPase (red), a plasma membrane marker, merge
(yellow). Only merge panels are shown. Dx-Hb treatment led to a prompt mobilization of FPN1 to the plasma membrane in donor
and p.A69T macrophages, but not in FD macrophages. (C) Macrophages were treated as above. Using the EEA-1 early endosomes
marker (red), in donor and p.A69T macrophages, both early endosomes and FPN1 are readily recruited to the plasma membrane
upon Dx-Hb exposure, whereas in p.G80S macrophages, FPN1 largely remains in the cytoplasm. (D) Cell ferritin content in macro-
phages treated was assayed as reported in the Patients and Methods section. In donor macrophages, Hb-Dx treatment led to an
appreciable decrease of intracellular ferritin, as compared to control cells, but this was not the case in G80S and A77D macrophages,
indicating intracellular iron retention. Data are presented as fold change versus control cells, set to 1.0. The ferritin values are mean6
SEM of three different cell preparations from a representative patient as compared to cell preparations from a blood donor. *P< 0.05.
(E) Medium iron content in macrophages treated was assayed as reported in the Patients and Methods section. Medium iron signifi-
cantly increased in donor macrophages exposed to Hb-Dx, but did not change in G80S and visibly decreased in A77D macrophages.
Data are presented as fold change versus control cells, set to 1.0. The iron values are mean6 SEM of three different cell preparations
from a representative patient as compared to cell preparations from a blood donor. *P< 0.05. (F) WB analysis of the same amount of
protein extracts (INPUT) from macrophages immunoprecipitated with anti FPN1 antibody (IP FPN1). Dx-Hb treatment did not
modify the FPN1 WB pattern. Abbreviations: Ctrl, control; Ig, immunoglobulin.
                                                                                                                                      
HEPATOLOGY, Vol. 65, No. 5, 2017 SABELLI ET AL.
1521
IAA, leading to the appearance of the proper 65-kDa
band. A similar FPN1 MW variability on WB analysis
has been previously reported in liver, duodenum, and
spleen of the same species by Canonne-Hergaux
et al.(4) This may be attributed to different tissue- or
species-specific posttranslational modifications of the
protein, as well as to the fact that solubilization of
highly hydrophobic proteins, especially multipass
membrane proteins, is not efficient. In our hands,
when protein extracts were subjected to enzymatic
digestion with PGNaseF and EndoH, spleen FPN1
was promptly digested by PGNaseF (in agreement
with Goncalves et al.(30)), but this was not the case for
human macrophages and THP1 cells, whereas in
HepG2 cells, both the 100-kDa MW and the 55-
kDa MW forms were partially digested. Yet, based on
the human FPN1 expression experiments in MDCK
cells, the peptide-competition experiments in human
macrophages, the FPN1 siRNA experiments, and the
response to Hepc inhibition, we can reasonably assume
that the identified bands in human macrophages are
electrophoretically different forms of FPN1. In order
to define the native status of FPN1, we performed gel
filtration of macrophage protein extracts. By size-
exclusion chromatography, endosome-associated pro-
teins form high-MW forms that are excluded, whereas
solubilized native proteins can be partitioned and
resolved. We conclude that native FPN1 in human
macrophages is monomeric, in agreement with previ-
ous studies showing that FPN1 is a monomer in vitro
and in vivo.(3,30-32)
After exposure of macrophages to Hepc, the physio-
logical FPN1 inhibitor, FPN1 was recruited to the cell
membrane, internalized, and progressively degraded.
Under this circumstance, the 62-kDa FPN1 form
appeared. Finally, when normal macrophages were
exposed to large amounts of Hb-iron, a physiological
stimulus for FPN1 synthesis and traffic to the mem-
brane, FPN1 rapidly shifted to the cell membrane
(along with endosomal vesicles).
FPN1 biology in A69T macrophages was similar to
that of normal macrophages under all experimental cir-
cumstances, except for the expected relative “resistance”
to Hepc-induced degradation (Fig. 4C, lanes 11 and
12). These findings are in agreement with a previous in
vitro study addressing p.A69T biology(12) and consis-
tent with the patient’s phenotype and the clinical diag-
nosis of FPN-associated hemochromatosis.(42)
A main objective of this study was to investigate
FPN1 expression in human macrophages from FD
patients carrying the p.A77D, p.G80S, and p.Val162-
del mutations and expressing the classic FD pheno-
type.(9,16,22,43-50) These FPN1 mutants have been
previously investigated in cell lines, but with
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FIG. 6. Model of FD. Normal FPN1 traffics within the endosomal-cell membrane compartment as a monomer to export iron in cells
with low iron turnover, such as enterocytes, and in larger quantity in cells with high iron turnover, such as tissue macrophages. In FD,
FPN1 can still traffic to the cell membrane and export iron in enterocytes, but fails to do so in tissue macrophages requiring a larger
amount of cell-surface–expressed FPN1.
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controversial results in terms of cellular localization
and iron transport capability.(3,5,6,20-22,46,49) In this
study, we primarily aimed at verifying whether FPN1
reaches the cell membrane in FD macrophages. We
found that FPN1 cycles in the early endosomal vesicles
are detectable at the plasma membrane in FD macro-
phages and respond to Hepc as in donor macrophages.
This does not support a “classic” dominant-negative
model proposed by previous in vitro studies, where the
mutant allele product is retained intracellularly and
precludes traffic and membrane targeting of the WT
allele product.(21,29) In general, in FD macrophages, a
larger fraction of FPN1 resides in the late-endosome/
lysosome compartment as compared to donor and
A69T macrophages, thus suggesting a higher degrada-
tion rate of FPN1 (Fig. 3A). In Fig. 4A, the immuno-
fluorescence signal in p.A77D, p.G80S, and
p.Val162del mutations persists after 3-6 hours of Hepc
exposure. We believe this pattern indicates that where-
as FPN1 is normally targeted to the cell membrane
and internalized upon Hepc exposure (Fig. 4B), in
lack-of-function macrophages a larger fraction of
FPN1 remains intracellularly, likely engaged/engulfed
within the degradation compartment, thus giving rise
to a more intense or persistent intracellular fluores-
cence signal. This is also suggested by the IP studies
reported in Fig. 4C, where a larger proportion of
“Hepc-internalized” FPN1 was detected in FD mac-
rophages as compared to donor macrophages (aster-
isks in p.G80S vs. Donor, Fig. 4C). We cannot
exclude that a different class of lack-of-function mac-
rophages FPN1 may differ in cycling efficiency, iron
export capacity, and/or Hepc sensitivity, based on
intrinsic structural properties of FPN1 and chemical
state of iron in the channel.(11,12) In fact, in p.G80S
FPN1 macrophages, we consistently detected a lower
faction of FPN1 committed to lysosomal degradation
as compared to p.A77D and p.Val162del macro-
phages (Figs. 3A and 4A). However, when FD mac-
rophages were exposed to a heme load, regardless of
the mutation, FPN1 was unable to reach the plasma
membrane and export iron (Fig. 5D,E). Under our
experimental conditions, FPN1 expression did not
increase upon heme exposure, as shown by the assess-
ment of FPN1 protein expression (see Fig. 5F) and
evaluation of FPN1 mRNA levels by RT-PCR (data
not shown). It seems that under such conditions,
when more FPN1 is needed at the cell surface, a
faulty mechanism, likely at the level of the degrada-
tion/cycling pathway, prevents sufficient FPN1 from
reaching the cell surface (Fig. 6).
In conclusion, based on the results of our ex vivo
experiments, we postulate that in FD, FPN1 mono-
mers can still reach the cell surface and export iron in
cells that are exposed in vivo to a relatively low flux
of iron, such as enterocytes (Fig. 6). However, in
cells undergoing in vivo high iron turnover, such as
tissue macrophages, a traffic jam in the degradation
and/or endocytic cycling pathways prevents sufficient
FPN1 from reaching the plasma membrane. In Fig.
6, for clarity, mutated FPN1 was not depicted at the
cell surface. However, this aspect has not been
addressed in the present article, and it cannot be
excluded that, as suggested by some reports,(3,9,12,20)
lack-of-function mutant FPN1 can also reach the
cell surface.
The proposed model is compatible with a mono-
meric protein structure and is consistent with the clini-
cal manifestations of FD patients in whom increased
iron deposits in hepatic macrophages (i.e., Kupffer
cells) are visible at young age,(15,16) transferrin satura-
tion is fairly normal throughout the patient’s life (indi-
cating that mutant FPN1 activity is not limiting for
intestinal iron transfer), but become critically low in
young female at menarche or after aggressive phleboto-
my,(15,16) when high iron demands for erythropoiesis
likely impose increased FPN1 traffic/cycling within
tissue macrophages.
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